BridgeBio Oncology Therapeutics (BBOT) Other Non-Current Assets (2023 - 2026)

BridgeBio Oncology Therapeutics has reported Other Non-Current Assets for 3 years, with the latest figure at $132000.0 in Q1 2026.

• Quarterly Other Non-Current Assets changed N/A year-over-year to $132000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $132000.0 (changed N/A YoY) and the FY2025 annual result came in at $12.6 million, up 9420.45% from the prior year.
• Other Non-Current Assets slipped to $132000.0 in Q1 2026 per BBOT's latest filing, from $12.6 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $12.6 million in Q4 2025 and troughed at $132000.0 in Q4 2024.
• A 3-year average of $3.7 million and a median of $212508.0 in 2024 frame the typical range for Other Non-Current Assets.
• The widest YoY moves for Other Non-Current Assets: up 9420.45% in 2025, down 9420.45% in 2025.
• Over 3 years, Other Non-Current Assets stood at $132000.0 in 2024, then surged by 9420.45% to $12.6 million in 2025, then plunged by 98.95% to $132000.0 in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $132000.0, $12.6 million, and $5.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.